117 related articles for article (PubMed ID: 17001296)
1. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296
[TBL] [Abstract][Full Text] [Related]
2. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
4. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
8. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
[TBL] [Abstract][Full Text] [Related]
9. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL; Lai MD; Huang JD
Drug Metab Dispos; 1999 Mar; 27(3):385-8. PubMed ID: 10064570
[TBL] [Abstract][Full Text] [Related]
10. A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype.
Ishiguro A; Kubota T; Sasaki H; Iga T
Clin Chim Acta; 2004 Sep; 347(1-2):217-21. PubMed ID: 15313161
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
12. A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Klein K; Tatzel S; Raimundo S; Saussele T; Hustert E; Pleiss J; Eichelbaum M; Zanger UM
Drug Metab Dispos; 2007 Aug; 35(8):1247-50. PubMed ID: 17460029
[TBL] [Abstract][Full Text] [Related]
13. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
14. The importance of heterogeneous nuclear ribonucleoprotein K on cytochrome P450 2D2 gene regulation: its binding is reduced in Dark Agouti rats.
Sakai N; Sakamoto KQ; Fujita S; Ishizuka M
Drug Metab Dispos; 2009 Aug; 37(8):1703-10. PubMed ID: 19420131
[TBL] [Abstract][Full Text] [Related]
15. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
[TBL] [Abstract][Full Text] [Related]
16. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction.
Endrizzi K; Fischer J; Klein K; Schwab M; Nüssler A; Neuhaus P; Eichelbaum M; Zanger UM
Anal Biochem; 2002 Jan; 300(2):121-31. PubMed ID: 11779102
[TBL] [Abstract][Full Text] [Related]
17. Inter-individual variation of several cytochrome P450 2D6 splice variants in human liver.
Denson J; Wu Y; Yang W; Zhang J
Biochem Biophys Res Commun; 2005 May; 330(2):498-504. PubMed ID: 15796910
[TBL] [Abstract][Full Text] [Related]
18. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Narimatsu S; Takatsu N; Yamano S; Inoue Y; Hanioka N; Kiryu K; Naito S; Gonzalez FJ; Yamamoto S
Chem Biol Interact; 2006 Jan; 159(1):47-57. PubMed ID: 16214121
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
Raimundo S; Fischer J; Eichelbaum M; Griese EU; Schwab M; Zanger UM
Pharmacogenetics; 2000 Oct; 10(7):577-81. PubMed ID: 11037799
[TBL] [Abstract][Full Text] [Related]
20. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]